1Brueggemeier RW. Aromatase inhibitors: new endocrine treatment of breast cancer. Semin Reprod Med ,2004,22( 1 ) :31-43.
2Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist, 2004,9 ( 2 ): 126-136.
3Forward DP, Cheung KL,Jackson L, et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer, 2004,90 ( 3 ):590-594.
4Baum M, Buzdar A. The curren status of aromatase inhibitors in management of breast cancer. Surg Clin N Am,2003,83:973-994.
5Mouridsen HT, Rose C, Brodie AH, et al. Challenges in the endocrine management of breast cancer. Breast,2003, ( Suppl 2 ): s2- s 19.
6Kaufmann M, Bajetta E, Dirix Ly, et al. Exemestane is superior to megestrol acetate after Tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase Ⅲ randomned doubleblind trial. J Clin Oncol,2000,18(7) :1399-1411.
7Simpson D, Curran MP,Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs, 2004,64 ( 11 ):1213-1230.
8Mouridsen H, Gershanovieh M, Sun Y, et al. Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole. Breast Cancer Group. J Clin Oncol,2003,21 ( 11 ) :2101-2109.
9Bonneterre J, Buzdar A, Nabh oltz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer,2001,92(9) :2247-2258.
10Thurlimann B, Hess D, Koberle D, et al. Anastrozole ( ‘Arimidex')versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET ( Tamoxifen or Arimidex'Randomized Group Efficacy and Tolerability ) trial. Breast Cancer Res Treat ,2004 ,85 ( 3 ) :247-254.
